A Novel Approach of Urinary Monohydroxyphenyl Metabolites Assay in Cancer Screening

Gan, Chao; Yao, Liqiong; Su, Na; Zhu, Jinhong; Li, Fēi; Li, Wen-Ti; Wang, Yanyun; Shi, Yong-Xin; Yu, Haitao

doi:10.7754/clin.lab.2019.190425

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most did not disclose any information regarding the type of urine or the preservation method used. Five (27.8%) of 18 studies discussed using urine as the source of metabolites, [217][218][219][220][221] four (22.2%) studies reported on proteins, [221][222][223][224] three (16.7%) on DNA, [225][226][227] three (16.7%) on oxidative stress markers, [228][229][230] two (11.1%) on RNA 226,231 and two (11.1%) on metals 232,233 (Table S1). These 18 publications showed some promising diagnostic urinary biomarkers for Pan-cancer applications.…”

Section: Pan-cancermentioning

confidence: 99%

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Jordaens

Zwaenepoel

Tjalma

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of this review was to explore the status of urine sampling as a liquid biopsy for noninvasive cancer research by reviewing used preanalytical parameters and protocols.We searched two main health sciences databases, PubMed and Web of Science. From all eligible publications (2010-2022), information was extracted regarding: (a) study population characteristics, (b) cancer type, (c) urine preanalytics, (d) analyte class, (e) isolation method, (f ) detection method, (g) comparator used, (h) biomarker type, (i) conclusion and (j) sensitivity and specificity. The search query identified 7835 records, of which 924 unique publications remained after screening the title, abstract and full text. Our analysis demonstrated that many publications did not report information about the preanalytical parameters of their urine samples, even though several other studies have shown the importance of standardization of sample handling. Interestingly, it was noted that urine is used for many cancer types and not just cancers originating from the urogenital tract. Many different types of relevant analytes have been shown to be found in urine. Additionally, future considerations and recommendations are discussed: (a) the heterogeneous nature of urine, (b) the need for standardized practice protocols and (c) the road toward the clinic. Urine is an emerging liquid biopsy with broad applicability in different analytes and several cancer types. However, standard

show abstract